Life Sciences Ontario (LSO) has appointed long-time MaRS client ArcticDX the 2012 Emerging Life Sciences Company of the Year. ArcticDX is a molecular diagnostic company that is commercializing prognostic, genetic-based tests for age-related macular degeneration and colon cancer, based on a deep IP portfolio of genetic biomarkers (check out their client profile video below to learn more!).
They join past winners YM Biosciences, Axela and Amorfix in this prestigious category, presented on a night when MaRS Board of Directors member Joe Rotman was likewise awarded LSO’s 2012 Lifetime Achievement Award (as reported yesterday).
ArcticDX is a recent graduate of the MaRS Incubator, a unique, two-storey section of the MaRS Centre that provides subsidized wet lab and/or office space to support the growth of eligible companies.
After spending three years there, and much time working with the Life Sciences and Healthcare Advisory team, ArcticDX has grown up and moved out into their own space (which is still in the MaRS Centre… we’re glad they chose to stick around!).
Their move out of the Incubator is a sign of their significant expansion into US and Canadian markets. With growing sales and increasing market penetration, ArcticDX is poised to continue their emergence as a model startup in the life sciences sector.